Riluzole, unlike the AMPA antagonist RPR119990, reduces motor impairment and partially prevents motoneuron death in the wobbler mouse, a model of neurodegenerative disease.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Experimental Neurology

• Publication date

  2006-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/J.EXPNEUROL.2005.11.010PMID 16386734
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Excitotoxicity in Amyotrophic Lateral Sclerosis: Selective Vulnerability of Motor Neurons

  2004cited by this paper
• Molecular mechanisms underlying specificity of excitotoxic signaling in neurons.

  2004cited by this paper
• Excitotoxicity in neurological diseases : new therapeutic challenge

  2004cited by this paper
• Riluzole slows the progression of neuromuscular dysfunction in the wobbler mouse motor neuron disease.

  2004cited by this paper
• Mechanisms underlying the riluzole inhibition of glutamate release from rat cerebral cortex nerve terminals (synaptosomes).

  2004cited by this paper
• Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)

  2003cited by this paper
• Impaired Spinal Cord Glutamate Transport Capacity and Reduced Sensitivity to Riluzole in a Transgenic Superoxide Dismutase Mutant Rat Model of Amyotrophic Lateral Sclerosis

  2003cited by this paper
• Creatine supplementation and riluzole treatment provide similar beneficial effects in copper, zinc superoxide dismutase (G93A) transgenic mice.

  2003cited by this paper
• The AMPA receptor antagonist NBQX prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis.

  2003cited by this paper
• The wobbler mouse

  2003cited by this paper
• Efficient three‐drug cocktail for disease induced by mutant superoxide dismutase

  2003cited by this paper
• Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).

  2002cited by this paper
• Riluzole enhances expression of brain‐derived neurotrophic factor with consequent proliferation of granule precursor cells in the rat hippocampus

  2002cited by this paper
• RPR 119990, a Novel α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid Antagonist: Synthesis, Pharmacological Properties, and Activity in an Animal Model of Amyotrophic Lateral Sclerosis

  2001cited by this paper
• Subcellular localization of calcium‐permeable AMPA receptors in spinal motoneurons

  2001cited by this paper
• GluR2 AMPA receptor subunit expression in motoneurons at low and high risk for degeneration in amyotrophic lateral sclerosis.

  2001cited by this paper
• Role of brain‐derived neurotrophic factor in wobbler mouse motor neuron disease

  2001cited by this paper
• Riluzole stimulates nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor synthesis in cultured mouse astrocytes.

  2001cited by this paper
• Transgenic SOD1 G93A mice develop reduced GLT‐1 in spinal cord without alterations in cerebrospinal fluid glutamate levels

  2001cited by this paper
• Glutamate transporters in the spinal cord of the wobbler mouse

  2001cited by this paper
• Neuroprotective agent riluzole dramatically slows inactivation of Kv1.4 potassium channels by a voltage-dependent oxidative mechanism.

  2001cited by this paper
• Dying neural cells activate glia through the release of a protease product

  2000cited by this paper
• AMPA Exposures Induce Mitochondrial Ca2+ Overload and ROS Generation in Spinal Motor Neurons In Vitro

  2000cited by this paper
• AMPA Receptor Calcium Permeability, GluR2 Expression, and Selective Motoneuron Vulnerability

  2000cited by this paper
• A novel neuroprotective mechanism of riluzole: direct inhibition of protein kinase C.

  2000cited by this paper
• Biochemical and pharmacological evidence of a functional role of AMPA receptors in motor neuron dysfunction in mnd mice

  1999cited by this paper
• Neurotrophic factors and neuro‐muscular disease: II. GDNF, other neurotrophic factors, and future directions

  1999cited by this paper
• Riluzole, a glutamate release inhibitor, and motor behavior

  1998cited by this paper
• Molecular biology of glutamate receptors in the central nervous system and their role in excitotoxicity, oxidative stress and aging.

  1998cited by this paper
• Riluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis

  1998cited by this paper
• Riluzole interacts with voltage-activated sodium and potassium currents in cultured rat cortical neurons.

  1998cited by this paper
• Regulation of growth factor gene expression in degenerating motoneurons of the murine mutant wobbler: a cellular patch-sampling/RT-PCR study.

  1998cited by this paper
• ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions.

  1997cited by this paper
• Differential Dependence on GluR2 Expression of Three Characteristic Features of AMPA Receptors

  1997cited by this paper
• A clinical trial of dextromethorphan in amyotrophic lateral sclerosis

  1997cited by this paper
• Calcium-permeable alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors: a molecular determinant of selective vulnerability in amyotrophic lateral sclerosis.

  1997cited by this paper
• Riluzole promotes survival of rat motoneurons in vitro by stimulating trophic activity produced by spinal astrocyte monolayers.

  1997cited by this paper
• Effects of the neuroprotective agent riluzole on the high voltage-activated calcium channels of rat dorsal root ganglion neurons.

  1997cited by this paper
• Glutamate receptor subunit 2‐selective antibody shows a differential distribution of calcium‐impermeable AMPA receptors among populations of neurons

  1997cited by this paper
• The GluR2 (GluR-B) hypothesis: Ca(2+)-permeable AMPA receptors in neurological disorders.

  1997cited by this paper
• Calcium‐permeable α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazole propionic acid receptors: A molecular determinant of selective vulnerability in amyotrophic lateral sclerosis

  1997cited by this paper
• Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis

  1996cited by this paper
• Evidence for multiple AMPA receptor complexes in hippocampal CA1/CA2 neurons

  1996cited by this paper
• Benefit of vitamin E, riluzole, and gababapentin in a transgenic model of familial amyotrophic lateral sclerosis

  1996cited by this paper
• Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. WALS Study Group. Western Amyotrophic Lateral Sclerosis Study Group.

  1996cited by this paper
• Excitotoxicity hypothesis

  1996cited by this paper
• The pharmacology and mechanism of action of riluzole

  1996cited by this paper
• Dose-ranging study of riluzole in amyotrophic lateral sclerosis

  1996cited by this paper
• A controlled trial of amino acid therapy in amyotrophic lateral sclerosis

  1996cited by this paper
• Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II.

  1996cited by this paper
• Motor Neurons Are Selectively Vulnerable to AMPA/Kainate Receptor-Mediated Injury In Vitro

  1996cited by this paper
• Glutamate transporter gene expression in amyotrophic lateral sclerosis motor cortex

  1996cited by this paper
• Selective loss of glial glutamate transporter GLT‐1 in amyotrophic lateral sclerosis

  1995cited by this paper
• The imbalance of brain large-chain aminoacid availability in amyotrophic lateral sclerosis patients treated with high doses of branched-chain aminoacids.

  1995cited by this paper
• CSF and plasma amino acid levels in motor neuron disease: elevation of CSF glutamate in a subset of patients.

  1995cited by this paper
• Effects of brain‐derived neurotrophic factor on motor dysfunction in wobbler mouse motor neuron disease

  1995cited by this paper
• Excess Extracellular and Low Intracellular Glutamate in Poorly Differentiating Wobbler Astrocytes and Astrocyte Recovery in Glutamine‐Depleted Culture Medium

  1995cited by this paper
• Down‐Regulation of AMPA Receptor Subunit GluR2 in Amygdaloid Kindling

  1995cited by this paper
• The effects of ciliary neurotrophic factor on motor dysfunction in wobbler mouse motor neuron disease

  1994cited by this paper
• Neuroprotective effects of riluzole in ALS CSF toxicity.

  1994cited by this paper
• High‐dose dextromethorphan in amyotrophic lateral sclerosis: Phase I safety and pharmacokinetic studies

  1994cited by this paper
• New mechanisms of excitatory transmitter neurotoxicity.

  1994cited by this paper
• A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group.

  1994cited by this paper
• Quantitative autoradiographic distribution of glutamate receptors in the cervical segment of the spinal cord of the wobbler mouse.

  1994cited by this paper
• The neuroprotective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area CA1.

  1993cited by this paper
• Neurotrophins promote motor neuron survival and are present in embryonic limb bud

  1993cited by this paper
• Anti-Glutamate Therapy in Amyotrophic Lateral Sclerosis: A Trial Using Lamotrigine

  1993cited by this paper
• Alterations of the GluR-B AMPA receptor subunit flip/flop expression in kainate-induced epilepsy and ischemia.

  1993cited by this paper
• Excitatory Amino Acid Receptor Antagonist in Murine Motoneuron Disease (The Wobbler Mouse)

  1992cited by this paper
• Brain-derived neurotrophic factor rescues spinal motor neurons from axotomy-induced cell death

  1992cited by this paper
• Pertussis toxin pretreatment abolishes the inhibitory effect of riluzole and carbachol on D-[3H]aspartate release from cultured cerebellar granule cells.

  1992cited by this paper
• Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis.

  1992cited by this paper
• Switch in glutamate receptor subunit gene expression in CA1 subfield of hippocampus following global ischemia in rats.

  1992cited by this paper
• A double-blind placebo-controlled trial ofl-threonine in amyotrophic lateral sclerosis

  1992cited by this paper
• Identification of a site in glutamate receptor subunits that controls calcium permeability

  1991cited by this paper
• Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis

  1990cited by this paper
• Abnormal glutamate metabolism in amyotrophic lateral sclerosis

  1987cited by this paper
• Murine motor neuron disease (the wobbler mouse): degeneration and regeneration of the lower motor neuron.

  1982cited by this paper
• A simplification of the protein assay method of Lowry et al. which is more generally applicable.

  1977cited by this paper
• A rapid radiochemical method for the determination of choline acetyltransferase

  1975cited by this paper
• An hereditary motor neurone disease with progressive denervation of muscle in the mouse: the mutant 'wobbler'.

  1968cited by this paper

• Riluzole attenuates glutamatergic tone and cognitive decline in AβPP/PS1 mice

  2020cites this paper
• Rethinking to riluzole mechanism of action: the molecular link among protein kinase CK1δ activity, TDP-43 phosphorylation, and amyotrophic lateral sclerosis pharmacological treatment

  2019cites this paper
• Long-term effects of the glucocorticoid receptor modulator cort 113176 in murine motoneuron degeneration.

  2019cites this paper
• Protective effects of the neurosteroid allopregnanolone in a mouse model of spontaneous motoneuron degeneration.

  2017cites this paper
• Excitatory-inhibitory imbalance in the brain of the wobbler mouse model of amyotrophic lateral sclerosis substantiated by riluzole and diazepam.

  2017cites this paper
• Lack of riluzole efficacy in the progression of the neurodegenerative phenotype in a new conditional mouse model of striatal degeneration

  2017cites this paper
• Organotypic Spinal Cord Culture: a Proper Platform for the Functional Screening

  2015cites this paper
• Is riluzole a potential therapy for Rett syndrome?

  2015cites this paper
• Neuroprotective effects of the Sigma-1 receptor (S1R) agonist PRE-084, in a mouse model of motor neuron disease not linked to SOD1 mutation.

  2014cites this paper
• The wobbler mouse, an ALS animal model

  2013influential citation
• Microglial SK3 and SK4 Currents and Activation State are Modulated by the Neuroprotective Drug, Riluzole

  2013cites this paper
• Neuroprotective Effects of Toll-Like Receptor 4 Antagonism in Spinal Cord Cultures and in a Mouse Model of Motor Neuron Degeneration

  2012cites this paper
• Progesterone effects on neuronal brain-derived neurotrophic factor and glial cells during progression of Wobbler mouse neurodegeneration.

  2012cites this paper
• Human Skeletal Muscle Stem Cell Antiinflammatory Activity Ameliorates Clinical Outcome in Amyotrophic Lateral Sclerosis Models

  2012cites this paper
• Antidepressant-like properties of oral riluzole and utility of incentive disengagement models of depression in mice

  2012cites this paper
• Mouse Models of Polyglutamine Diseases in Therapeutic Approaches: Review and Data Table. Part II

  2012cites this paper
• Progesterone prevents mitochondrial dysfunction in the spinal cord of wobbler mice

  2012influential citation
• Neuroprotective effects of riluzole in early phase Parkinson's disease on clinically relevant parameters in the marmoset MPTP model.

  2012cites this paper
• Neural precursors (NPCs) from adult L967Q mice display early commitment to "in vitro" neuronal differentiation and hyperexcitability.

  2012cites this paper
• Human Skeletal Muscle Stem Cells' Anti-inflammatory Activity Ameliorates Clinical Outcome in Amyotorophic Lateral Sclerosis Model

  2011cites this paper
• Promoting the survival, migration and integration of Schwann cells by over-expression of polysialic acid

  2011cites this paper
• Pharmacological interventions for spinal cord injury: where do we stand? How might we step forward?

  2011cites this paper
• Review of the Use of the Glutamate Antagonist Riluzole in Psychiatric Disorders and a Description of Recent Use in Childhood Obsessive-Compulsive Disorder

  2010cites this paper
• Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial.

  2010cites this paper
• Neuropathologic and Biochemical Changes During Disease Progression in Liver X Receptor &bgr;−/− Mice, A Model of Adult Neuron Disease

  2010cites this paper
• Calcium dysregulation in amyotrophic lateral sclerosis.

  2010cites this paper
• Chemical-genetic screen identifies riluzole as an enhancer of Wnt/β-catenin signaling in melanoma.

  2010cites this paper
• Release of [3H]D-aspartate induced by K+-stimulation is increased in the cervical spinal cord of the wobbler mouse: a model of motor neuron disease.

  2009cites this paper
• Experimental models for the study of neurodegeneration in amyotrophic lateral sclerosis

  2009cites this paper
• Stage Dependent Effects of Progesterone on Motoneurons and Glial Cells of Wobbler Mouse Spinal Cord Degeneration

  2009influential citation
• Combined riluzole and sodium phenylbutyrate therapy in transgenic amyotrophic lateral sclerosis mice

  2009cites this paper
• Effectiveness of riluzole in suppressing spasticity in the spinal cord injured rat.

  2009cites this paper
• Drug screening of neuroprotective agents on an organotypic-based model of spinal cord excitotoxic damage

  2009influential citation
• Estudio del efecto neuroprotector de tratamientos farmacológicos en un modelo in vitro de lesión excitotóxica de médula espinal de rata basado en cultivos organotípicos

  2009cites this paper
• Recombinant human TNF-binding protein-1 (rhTBP-1) treatment delays both symptoms progression and motor neuron loss in the wobbler mouse.

  2008cites this paper
• Endogenous Erythropoietin as Part of the Cytokine Network in the Pathogenesis of Experimental Autoimmune Encephalomyelitis

  2008cites this paper
• The heterogeneity of amyotrophic lateral sclerosis: a possible explanation of treatment failure.

  2007cites this paper
• Expression of AMPA and NMDA receptor subunits in the cervical spinal cord of wobbler mice

  2006cites this paper
• Nonhematopoietic Erythropoietin Derivatives Prevent Motoneuron Degeneration In Vitro and In Vivo

  2006cites this paper